Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
, 2016 Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita +2 more
core +1 more source
Haematologica, 2020 We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen +19 more
doaj +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
, 2016 The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
Case Reports in Oncology, 2020 Polycythemia vera is one of the myeloproliferative neoplasms that is distinguished by the uncontrolled production of blood cells and an increased red cell mass due to acquired JAK2 mutation.
Ahmed M. Abdalhadi, Mohamed A. Yassin
doaj +1 more source
From leeches to personalized medicine: evolving concepts in the management of polycythemia vera
Haematologica, 2017 Polycythemia vera is a clonal disorder of hematopoietic stem/progenitor cells. It manifests as an expansion of red cell mass. It is the most common chronic myeloproliferative neoplasm. In virtually all cases, it is characterized by a V617F point mutation
Alessandro M. Vannucchi
doaj +1 more source
Thrombotic and hemorrhagic complications in idiopathic erythrocytosis [PDF]
, 2017 We report clinical features of a large cohort of patients with IE compared to a cohort of patients with PV, focusing on the thrombotic and hemorrhagic ...
Bertozzi, Irene +5 more
core +1 more source
The Impact of Current Treatment on The Symptomatology and Complications of Patients with Polycythemia Vera [PDF]
Documenta HaematologicaIntroduction: polycythemia vera is a Ph-negative relatively indolent chronic myeloproliferative disease, with a high risk of arterial and venous thrombosis, affecting patient survival.
Marc-Tudor DAMIAN +2 more
doaj +1 more source
Isolated cerebellar infarction in a case of JAK 2 mutation-negative polycythemia vera: A case report
Brain Circulation, 2022 Polycythemia vera is a myeloproliferative disorder caused by clonal expansion of erythroid precursors in the bone marrow commonly due to a mutation in the Janus kinase 2 (JAK2) gene located in the short arm of chromosome 9. Hyperviscosity of blood due to
Prasad Krishnan
doaj +1 more source
Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms [PDF]
, 2010 We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally.
Cheung, AMS +4 more
core +1 more source
Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms. [PDF]
, 2014 Myeloproliferative neoplasms (MPNs) are clonal hematological diseases in which cells of the myelo-erythroid lineage are overproduced and patients are predisposed to leukemic transformation.
de Haan, Gerald +3 more
core +1 more source